Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 27, 2026 09:00 ET | Source: Nextech Systems, Inc.

Nextech Pioneers New Era in Clinical Documentation with Launch of AI-Powered Cora Scribe

Tampa, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Specialty-specific clinical documentation requires more than a generic, automated note taker to truly improve the charting process. Today, Nextech – an...
January 27, 2026 09:00 ET | Source: Muscular Dystrophy Association

Organizations Join Forces to Map How Human Muscle Regenerates

New York, Jan. 27, 2026 (GLOBE NEWSWIRE) -- A pivotal scientific collaboration born out of the Muscular Dystrophy Association’s (MDA) Muscle Regeneration Summit is advancing a first-of-its-kind...
January 27, 2026 09:00 ET | Source: Evosep

Evosep Launches IQ/OQ Protocols for the Evosep Eno System at WCBP 2026

Evosep announces a major advancement in QA for pharmaceutical and regulated laboratories with the introduction of IQ/OQ protocols for its Evosep Eno system
January 27, 2026 08:50 ET | Source: Myriad Genetics, Inc.

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

Myriad advances Precise MRD toward a March 2026 launch, backed by new breast and colorectal cancer data showing ultrasensitive ctDNA detection.
January 27, 2026 08:45 ET | Source: Ernexa Therapeutics Inc.

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune...
January 27, 2026 08:30 ET | Source: CytoDyn Inc.

CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer

VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized...
January 27, 2026 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome

Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to...
January 27, 2026 08:30 ET | Source: TRIMEDX

TRIMEDX named recipient of Modern Healthcare’s Best in Business Award in Cybersecurity category

Indianapolis, Indiana, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TRIMEDX―a leading independent clinical asset management company delivering clinical engineering services, clinical asset informatics, and...
January 27, 2026 08:30 ET | Source: Imviva Biotech

Imviva Biotech Receives FDA Orphan Drug Designation for CTD402 for the Treatment of T-Cell Leukemia and Lymphoma

BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that the U.S. Food and...
January 27, 2026 08:00 ET | Source: Teva Pharmaceutical Industries Ltd

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

Actor and comedian, Will Forte, opens up about his brother-in-law's journey with Huntington’s disease (HD) and chorea through Teva’s Honestly HD programHD is a rare, progressive genetic disorder often...